Clinical Trials | December 03, 2025
Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Angelini Ventures has already invested €125 million in 22 startups
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Now a test that offers new precision in prostate cancer detection
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
